March 2021

March 31, 2021

From the Co-Chairs, March 2021

What will 'clean-up' and recovery after COVID-19 entail?
March 31, 2021

Now Enrolling: EA6194 for Operable Melanoma

This phase II study, led by Dr. Ahmad Tarhini, is testing neoadjuvant treatment with pembrolizumab alone versus pembrolizumab and an investigational drug called CMP-001
March 31, 2021

Now Enrolling: PrE0506 / DREAM3R for Patients with Malignant Pleural Mesothelioma

This phase III study, led by Drs. Patrick Forde and Anna Nowak, is evaluating durvalumab immunotherapy during and after standard chemotherapy versus chemotherapy alone
March 31, 2021

Trial Spotlight: Amer Zeidan on the BLAST MRD CML 1 Study for Chronic Myeloid Leukemia

The EA9171 phase II trial aims to determine if adding pembrolizumab immunotherapy to standard-of-care TKI therapy helps more patients achieve undetectable minimal residual disease and allows them to discontinue TKI therapy
March 31, 2021

Institution Spotlight: Puerto Rico Minority Underserved NCORP

A member of ECOG-ACRIN since 1990
March 31, 2021

News in Brief, March 2021